Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of PHA-848125AC as second-line treatment in pemetrexed-pretreated malignant pleural mesothelioma
2008-005831-13Phase 2Completed
- Sponsor
- Nerviano Medical Sciences
- Start
- Mar 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of milciclib in pleural mesothelioma, sponsored by Nerviano Medical Sciences. Primary endpoints: 12-week progression-free rate and Time to tumor progression. Started Mar 2009; status: completed.
02
Drugs
milciclib
03
Conditions
pleural mesothelioma
Beyond the preview
Go deeper on 2008-005831-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005831-13.